FORT LAUDERDALE, Fla., Jan. 6, 2017 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that Matthew H.J. Kim, Founder, Chairman and Chief Executive Officer, will present at two upcoming conferences in San Francisco: the BioLink 2017 China Healthcare Industry Investment and Licensing Conference, taking place January 8, 2017 at the San Francisco Hilton Airport Hotel, and Medtech Showcase 2017 (at Biotech Showcase™), taking place at the Parc 55 San Francisco, January 10 – 11, 2017.
Mr. Kim will speak at the BioLink 2017 conference on Sunday, January 8 at 3:30 p.m. PST, and will speak at the Medtech Showcase 2017 on Wednesday, January 11 at 10:15 a.m. PST. In his presentations, Mr. Kim will review Vigilant Biosciences' business strategy and opportunities in regards to the commercialization of its OncAlert® Oral Cancer and OncAlert Labs product lines, as well as other products in the Company's pipeline.
About Vigilant Biosciences Products
Vigilant Biosciences OncAlert Oral Cancer product line is based on patented technology that measures soluble CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. Vigilant's products currently include the OncAlert Labs OraMark™ Test, a laboratory developed test available only through OncAlert Labs, a CLIA certified laboratory; and the OncAlert Oral Cancer product line, which includes the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test, both CE Marked and available in select markets outside the United States.
Vigilant's accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus).
About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. For those who survive oral cancer diagnosed in the later stages, the treatment is painful, debilitating and often disfiguring. In addition, patients often struggle with eating and drinking, communicating and self image. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.
For more information or to set up a meeting with Vigilant Biosciences at BioLink 2017 or Medtech Showcase 2017, please contact Jennifer Moritz at jmoritz@0to5.com.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMark™ Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.
SOURCE Vigilant Biosciences, Inc.